help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on May 6, 2008
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2007-1508
This Article
Right arrow Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Google Scholar
Right arrow Articles by Ivaska, K. K.
Right arrow Articles by Obrant, K. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ivaska, K. K.
Right arrow Articles by Obrant, K. J.
Related Collections
Right arrow Calcium and Bone Metabolism
Right arrow Female Endocrinology

Submitted on July 6, 2007
Accepted on April 24, 2008

Serial assessment of serum bone metabolism markers identifies women with the highest rate of bone loss and osteoporosis risk

Kaisa K. Ivaska*, Janaka Lenora, Paul Gerdhem, Kristina Åkesson, H. Kalervo Väänänen, and Karl J. Obrant

Clinical and Molecular Osteoporosis Research Unit, Lund University, Department of Orthopaedics, Malmö University Hospital, SE-20502 Malmö, Sweden; University of Turku, Institute of Biomedicine, Department of Anatomy, FI-20520 Turku, Finland; Karolinska Institute, Department of Orthopaedics, Karolinska University Hospital, SE-14186 Stockholm, Sweden

* To whom correspondence should be addressed. E-mail: kaisa.ivaska{at}med.lu.se.

Context: One of the important challenges in the management of osteoporosis is to identify women who are at high risk of developing osteoporosis and fragility fractures.

Objective: To evaluate if assessment of bone metabolism at multiple occasions can identify women with the highest risk for bone loss.

Design: The Malmö OPRA study is an ongoing longitudinal study. Participants have been evaluated at baseline and after 1, 3 and 5 years.

Setting: Population-based study.

Participants: 1044 women, all 75 years old at baseline.

Main outcome measures: Seven bone turnover markers were assessed at baseline, 1, 3 and 5 years (n=573). Five year change in areal bone mineral density (aBMD) was also determined.

Results: Baseline markers correlated weakly to change in total body aBMD. The associations were more pronounced when the average of the baseline and 1-year measurements was used (standardized regression coefficients -0.12 to -0.23, p<0.01). Adding the 3-year and 5-year measurement further strengthened the correlation (regression coefficients up to -0.30 (p<0.001)). Women with constantly high turnover lost significantly more bone at total body (-2.6%) than women with intermediate (-1.6%) or low turnover (-0.2%, p for trend <0.001). They also had a greater decrease in hip BMD (-8.3%, -6.0% and -5.1%, respectively, p=0.010). Results were similar also in the subgroup of women with osteopenia.

Conclusions: Our results suggest that serial assessment of bone turnover improves the identification of women with the highest rate of bone loss and osteoporosis risk.


Key words: bone turnover markers • bone loss • osteoporosis • longitudinal • prospective







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2008 by The Endocrine Society